Site Map
Product Pages Catalogue Numbers 1801 - 1900
| Cat. No. | Product Name & Pharmacological Action |
|---|---|
| 1801 | WAY 161503 hydrochloride |
| Potent, selective 5-HT2C agonist | |
| 1802 | 2B-(SP) |
| Selective GSK-3 phosphopeptide substrate | |
| 1803 | ITE |
| Endogenous agonist for the transcription factor aryl hydrocarbon receptor | |
| 1804 | SR 2640 hydrochloride |
| Potent, selective LTD4 /LTE4 receptor antagonist | |
| 1805 | Gly-Pro-Arg-Pro |
| Inhibits fibrin polymerisation | |
| 1806 | SR 33805 oxalate |
| Ca2+ channel blocker; binds allosterically to distinct site on L-type channels | |
| 1807 | 2-Methoxyestradiol |
| Apoptotic and antiangiogenic agent | |
| 1808 | E-4031 dihydrochloride |
| K+ (HERG) channel blocker; inhibits rapid delayed rectifier K+ current (IKr) | |
| 1809 | Altanserin hydrochloride |
| 5-HT2 receptor antagonist | |
| 1810 | Raclopride |
Potent, selective D2/D3 antagonist |
|
| 1811 | Modafinil |
| Psychostimulant | |
| 1813 | Indirubin-3'-oxime |
| GSK-3β inhibitor. Also inhibits other protein kinases | |
| 1814 | N-ArachidonylGABA |
| Inhibits pain in vivo | |
| 1815 | Palmitoylisopropylamide |
Inhibitor of FAAH |
|
| 1816 | ICI 63197 |
| PDE4 inhibitor | |
| 1818 | Octreotide |
| sst2, sst3 and sst5 agonist | |
| 1819 | Demethylasterriquinone B1 |
| Selective insulin RTK activator | |
| 1821 | YM 976 |
| PDE4 inhibitor | |
| 1822 | AMPA Receptor TocrisetTM |
| Selection of 5 AMPA receptor ligands (Cat. Nos. 0254, 0306, 1044, 0713 and 1454) | |
| 1823 | NMDA Receptor - Glycine Site TocrisetTM |
| Selection of 5 NMDA receptor (glycine site) ligands (Cat. Nos. 0219, 0281, 0742, 1493 and 0237) | |
| 1824 | Kainate Receptor TocrisetTM |
| Selection of 5 kainate receptor ligands (Cat. Nos. 0222, 1107, 0903, 1045 and 1454) | |
| 1825 | Mixed NMDA Receptor TocrisetTM |
| Selection of 5 mixed NMDA receptor ligands (Cat. Nos. 0114, 0312, 0106, 0924 and 1241) | |
| 1826 | Group I mGlu Receptor TocrisetTM |
| Selection of 5 group I mGlu receptor ligands (Cat. Nos. 0805, 0188, 1237, 1212 and 0337) | |
| 1827 | Group II mGlu Receptor TocrisetTM |
| Selection of 5 group II mGlu receptor ligands (Cat. Nos. 1208, 0975, 1209, 0971 and 0337) | |
| 1828 | Group III mGlu Receptor TocrisetTM |
| Selection of 5 group III mGlu receptor ligands (Cat. Nos. 0103, 1220, 0972, 0803 and 1209) | |
| 1829 | Mixed mGlu Receptor TocrisetTM |
| Selection of 5 mixed mGlu receptor ligands (Cat. Nos. 0805, 0975, 0103, 0337 and 1209) | |
| 1830 | Excitatory Amino Acid Transporter Inhibitor TocrisetTM |
| Selection of 5 EAAT inhibitors (Cat. Nos. 0183, 0298, 1223, 0111 and 0903) | |
| 1831 | HS 014 |
| Selective MC4 receptor antagonist | |
| 1832 | HS 024 |
| Highly potent MC4 receptor antagonist | |
| 1835 | FRATide |
| GSK-3 inhibitor | |
| 1836 | Seglitide |
| sst2 and sst5 agonist | |
| 1838 | IRL-2500 |
| Potent ETB antagonist | |
| 1839 | BIM 23127 |
| NMB receptor antagonist. Also UT-II receptor antagonist | |
| 1840 | Fostriecin sodium salt |
| Potent PP2A and PP4 inhibitor | |
| 1842 | RHC 80267 |
| Diacylglycerol lipase inhibitor. Weak inhibitor of PLC and PLA2 | |
| 1843 | CYN 154806 |
| Selective sst2 antagonist | |
| 1844 | BIM 23056 |
| Somatostatin receptor ligand | |
| 1845 | Ac2-26 |
| Annexin/lipocortin 1-mimetic; inhibits leukocyte extravasation | |
| 1846 | Ac2-12 |
| Annexin/lipocortin 1-mimetic; inhibits leukocyte extravasation | |
| 1847 | Eticlopride hydrochloride |
| Selective D2/D3 antagonist | |
| 1849 | EMD 66684 |
| Potent, selective non-peptide AT1 antagonist | |
| 1850 | Exo1 |
| Inhibits Golgi-ER traffic; blocks exocytosis | |
| 1851 | Glucagon-like peptide 1 (1-37) (human, bovine, guinea pig, mouse, rat) |
| Endogenous pancreatic peptide | |
| 1852 | (S)-(-)-Blebbistatin |
| Selective inhibitor of myosin II. Active enantiomer | |
| 1853 | (R)-(+)-Blebbistatin |
| Inactive enantiomer of the myosin II inhibitor (±)-blebbistatin (Cat. No. 1760) | |
| 1854 | Ro 60-0175 fumarate |
| Potent, selective 5-HT2C agonist | |
| 1856 | L-165,041 |
| Potent PPARδ agonist | |
| 1857 | Burimamide oxalate |
| Mixed H2/H3 antagonist | |
| 1858 | Impentamine dihydrobromide |
| Selective H3 antagonist | |
| 1860 | Eltoprazine hydrochloride |
| 5-HT1 receptor agonist/partial agonist | |
| 1862 | PRIMA-1 |
| Restores mutant p53 activity; induces apoptosis | |
| 1866 | MRS 1845 |
| Potent SOC inhibitor; blocks capacitative Ca2+ entry | |
| 1867 | NSC 663284 |
| Potent, selective Cdc25 phosphatase inhibitor | |
| 1868 | U0124 |
| Inactive analogue of U0126 (Cat. No. 1144) | |
| 1869 | Ipsapirone |
| Selective 5-HT1A agonist | |
| 1870 | BTS |
| Selective inhibitor of skeletal muscle myosin II ATPase activity | |
| 1871 | α1-Adrenoceptor TocrisetTM |
| Selection of 5 α1-adrenoceptor ligands (Cat. Nos. 1052, 0888, 1006, 0946 and 0623) | |
| 1872 | α2-Adrenoceptor TocrisetTM |
| Selection of 5 α2-adrenoceptor ligands (Cat. Nos. 1030, 0425, 0928, 1133 and 0891) | |
| 1873 | β-Adrenoceptor Agonist TocrisetTM |
| Selection of 3 β-adrenoceptor agonists (Cat. Nos. 0948, 1747 and 1660) | |
| 1874 | β-Adrenoceptor Antagonist TocrisetTM |
| Selection of 3 β-adrenoceptor antagonists (Cat. Nos. 1024, 0821 and 1511) | |
| 1875 | Mixed Adrenergic TocrisetTM |
| Selection of 5 mixed adrenoceptor ligands (Cat. Nos. 0888, 0425, 1747, 0623 and 0952) | |
| 1876 | Histamine H3 Receptor TocrisetTM |
| Selection of 5 histamine H3 receptor ligands (Cat. Nos. 0729, 0569, 0752, 0779 and 0644) | |
| 1877 | Serotonin Uptake Inhibitor TocrisetTM |
| Selection of 5 serotonin uptake inhibitors (Cat. Nos. 0596, 1427, 0457, 0927 and 1033) | |
| 1878 | MAPK Cascade Inhibitor TocrisetTM |
| Selection of 5 MAPK cascade inhibitors (Cat. Nos. 1110, 1213, 1321, 1144 and 1202) | |
| 1879 | MAPK Inhibitor TocrisetTM |
| Selection of 5 MAPK inhibitors (Cat. Nos 1213, 1202, 1264, 1496 and 1144) | |
| 1880 | Mixed Kinase Inhibitor TocrisetTM |
| Selection of 5 mixed kinase inhibitors (Cat. Nos. 0741, 1277, 1288, 1289 and 1285) | |
| 1881 | Phosphodiesterase Inhibitor TocrisetTM |
| Selection of 5 phosphodiesterase inhibitors (Cat. Nos. 0915, 1504, 0415, 1349 and 1046) | |
| 1882 | PKA TocrisetTM |
| Selection of 5 PKA modulators (Cat. Nos. 1337, 1140, 1099, 1288 and 1603) | |
| 1883 | cGMP Dependent Kinase Inhibitor Peptide |
| Inhibitor of protein kinases G and A | |
| 1884 | [D-Trp7,9,10]-Substance P |
| Inhibits M1 ACh receptor activation of Gq/11 | |
| 1885 | MLCK inhibitor peptide 18 |
| Selective inhibitor of myosin light chain kinase | |
| 1886 | Neuropeptide SF (human) |
| Implicated in pain modulation and opioid function | |
| 1887 | PKC fragment (530-558) |
| Potent activator of protein kinase C | |
| 1889 | [Leu5]-Enkephalin |
| Endogenous opioid agonist peptide | |
| 1890 | Neuromedin C (porcine) |
| Mammalian bombesin-like peptide | |
| 1891 | Calcineurin Autoinhibitory Peptide |
| Selective calcineurin inhibitor | |
| 1892 | Amyloid b-Peptide (10-20) (human) |
| Amyloid β-peptide; substrate for MMP-2 | |
| 1893 | Alytesin |
| Amphibian bombesin-like peptide | |
| 1894 | Amyloid β-Peptide (12-28) (human) |
| Amyloid β-peptide; minimum required for binding to brain proteins | |
| 1896 | Mastoparan X |
| G protein activator peptide | |
| 1897 | Angiotensin IV (human) |
| Agonist for the AT4 receptor | |
| 1898 | Guanylin (human) |
| Endogenous activator of intestinal guanylyl cyclase | |
| 1899 | Sarafotoxin S6a |
| Endothelin receptor agonist | |
| 1900 | [Ala107]-MBP (104-118) |
| Protein kinase C inhibitor | |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | All |
[top]